A Study to Evaluate the Effects of a Marine Lipid Oil Concentrate Formulation on Inflammation

Inflammation Clinical Trial

Official title:

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of a Specialized Pro-Resolving Mediator Formulation on Inflammation in Individuals Who Are Overweight to Mildly Obese and Otherwise Generally Healthy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04269876
• Other study ID #: CL103
• Status: Terminated
• Phase: N/A
• Start date: October 31, 2019
• Est. completion date: September 30, 2021

Study information

• Verified date: July 2022
• Source: Supplement Formulators, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the efficacy and safety of a Marine Lipid Oil Concentrate formulation on inflammatory biomarkers and overall well-being in male and female subjects who are overweight to mildly obese, but otherwise generally healthy.

Description:

This is a double-blind randomized, placebo-controlled study to evaluate the effects of a Marine Lipid Oil Concentrate formulation on inflammation.. Each subject will receive a specific dose of the study product (A) to be taken once daily with a specific dose of the study product (B) to be taken once daily for a total of 60 days.

Participants will receive questionnaires, assessments, blood tests, vital signs and a body composition analysis.

The primary objective is the assessment of the change in the blood levels of hs-CRP in response to the Marine Lipid Oil Concentrate formulation relative to screening/baseline compared to placebo.

The secondary objective is the assessment of the change in the in response to the Marine Lipid Oil Concentrate formulation relative to screening/baseline compared to placebo for Interleukin-6 (IL-6), Tumor necrosis factor (TNF-alpha), Erythrocyte Sedimentation Rate (ESR), Fibrinogen Activity, B-type natriuretic peptide (BNP), Ferritin, Blood lipid levels (Total Cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Triglycerides), Short Form-36 (SF-36) Health Survey scores and the Medical Symptoms Questionnaire

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: September 30, 2021
• Est. primary completion date: September 30, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Ambulatory, male or female, 35-75 years of age

2. A BMI of 23-34.9

3. hs-CRP level of 1-7.5 mg/L

4. Generally healthy and having no significant difficulty with digestion or absorption of food

5. Has been generally weight stable for the past six months (+/- 6 lbs.)

6. Willing and able to give written informed consent

7. Clearly understands the procedures and study requirements

8. Willing and able to comply with all study procedures, including following the recommendations to maintain their usual diet and regular activity, as per protocol

9. Able to communicate, including reading, in English

10. Have not taken any nutritional supplements that may contain any of the components of the study product for a minimum of 14 days before Screening/baseline

Exclusion Criteria:

1. Having smoked any cigarette, electronic cigarette, cigar, pipe, or used a recreational drug as well as any product containing cannabidiol (CBD) and tetrahydrocannabinol in the past 30 days.

2. Donated blood within 30 days before Screening/baseline

3. Inability to provide a venous blood sample

4. Participation in another study within 30 days before Screening/baseline

5. Being pregnant or planning on becoming pregnant during study participation; or breast feeding

6. History of allergy or sensitivity to any component of the study products

7. Currently taking a lipid lowering medication or dietary supplement

8. Currently taking a medication or dietary supplement specifically for pain or inflammation including curcumin and unwilling to washout (i.e., stop taking) for 14 days before Screening/baseline

9. Currently taking or having taken a fish oil, krill oil, omega-3 supplement and omega-3 prescription drugs within the past 3 months before Screening/baseline

10. Currently taking or having taken pain medications or anti-inflammatory medication(s) (e.g., aspirin, NSAIDs, Cyclooxygenase-2 (COX-2) inhibitors, and corticosteroids) within 14 days before Screening/baseline or in the judgment of the Study Investigator/Sub-I would not preclude participation in the study

11. Having been diagnosed, received medical treatment, or taking medication daily for the following medical condition(s):

• Acute or chronic inflammatory or autoimmune disease (including rheumatoid arthritis, system lupus erythematosus, ankylosing spondylitis, Sjögren's syndrome, polymyalgia rheumatica, inflammatory bowel disease, and psoriatic arthritis)

12. Presence of active or recurring clinically significant conditions as follows:

• Diabetes mellitus or other endocrine disease

• Acute infection

• Active periodontal disease

• Cardiovascular disease including heart and blood vessel disease, arrhythmia, heart attack, stroke, or heart valve problem

• Gastrointestinal disease including gallbladder problems, gallstones, or biliary tract obstruction

• Thyroid disease (unless on a stable dose of medication for 3 months before screening and unlikely to change medication or dose during the study)

• Hypertension (unless on a stable dose of medication for 3 months screening and unlikely to change medication or dose during the study)

• Neurologic condition/disease

• Cancer (unless skin cancer other than melanoma which has been treated > 3 years before Screening/baseline)

• Liver, pancreatic, and kidney disease

• Pulmonary disease

• Blood coagulation disorder or other hematologic disease

• Other condition or medication use that would preclude participation in the study in the judgment of the Investigator/Sub-I

13. Currently taking any medications or treatment for a psychiatric disorder (bipolar disorder,manic disorder, schizophrenia, apathetic [inherited] disorder), that include antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs), tricyclic and atypical antidepressants; benzodiazepines; central nervous system (CNS) depressants, dextromethorphan, meperidine, monoamine oxidase inhibitors (MAOIs); pentazocine, phenothiazines, and tramadol. These may preclude participation in the study dependent on the judgment of the Investigator/Sub-I.

14. Currently taking or having taken within the 30 days before Screening/baseline any hormone replacement therapy (including dehydroepiandrosterone (DHEA), estrogen, progesterone, or testosterone; except those utilized as a method of birth control and which have been taken for > 3 months, with no anticipated change for the duration of the study)

15. Having had a surgical procedure or having an internal medical device which, in the judgment of the Study Investigator/Sub-I, would preclude participation in the study

16. Having abnormal screening laboratory test values including bilirubin > 2.5 x upper limit of normal (ULN), aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and alanine transaminase (ALT)/serum glutamic-pyruvic transaminase (SGPT) > 2.5 x ULN, serum creatinine > 1.5 mg/dL, blood glucose < 85 mg/dL or > 110 mg/dL, hs-CRP < 1.0 mg/L or > 5 mg/L, or other lab test result(s) that would preclude study participation in the judgement of the Study Investigator/Sub-I

17. Having blood pressure readings at Screening/baseline > 140 systolic or > 90 diastolic on two consecutive readings unless permitted to proceed to the next visit in the judgment of the Study Investigator/Sub-I

18. Currently consumes more than 7 standard alcoholic drinks per week for women and 14 drinks per week for men (a standard alcoholic drink is defined as one bottle/can of beer, one glass of wine, or one ounce of hard liquor)

19. Unable or unwilling to avoid consuming grapefruit juice or fresh grapefruit, Seville oranges, and tangelos

20. History of known or suspected substance abuse (e.g., alcohol, opiates, benzodiazepines or amphetamines).

21. Having any other circumstance that precludes study participation in the judgment of the Study Investigator/Sub-I, including use of other nutritional supplements, which will be evaluated on a case-by-case basis.

Related Conditions & MeSH terms

• Inflammation
• Inflammatory Response

Intervention

Dietary Supplement:
• Marine Lipid Oil Concentrate
Marine Lipid Oil Concentrate softgels
• Dietary Supplement
Dietary Supplement capsules
• Placebo
Placebo softgels
• Placebo
Placebo capsules

Locations

Country	Name	City	State
United States	Lfie Extension Clinical Reseach, Inc.	Fort Lauderdale	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Supplement Formulators, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (30)

Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol. 2013 Aug;169(8):1672-92. doi: 10.1111/bph.12131. — View Citation

Bassiouny AR, Zaky A, Kandeel KM. Alteration of AP-endonuclease1 expression in curcumin-treated fibrotic rats. Ann Hepatol. 2011 Oct-Dec;10(4):516-30. — View Citation

Buhrmann C, Mobasheri A, Busch F, Aldinger C, Stahlmann R, Montaseri A, Shakibaei M. Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 2011 Aug 12;286(32):28556-66. doi: 10.1074/jbc.M111.256180. Epub 2011 Jun 13. — View Citation

Campbell MS, Ouyang A, I M K, Charnigo RJ, Westgate PM, Fleenor BS. Influence of enhanced bioavailable curcumin on obesity-associated cardiovascular disease risk factors and arterial function: A double-blinded, randomized, controlled trial. Nutrition. 2019 Jun;62:135-139. doi: 10.1016/j.nut.2019.01.002. Epub 2019 Jan 11. — View Citation

Campbell, M., Berrones, A., Krishnakumar, I. M., Charnigo, R. J., Westgate, P. M., & Fleenor, B. S. (2017). Responsiveness to curcumin intervention is associated with reduced aortic stiffness in young, obese men with higher initial stiffness. J Funct Foods, 29, 154-160.

Chainani-Wu N, Madden E, Lozada-Nur F, Silverman S Jr. High-dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen planus. J Am Acad Dermatol. 2012 May;66(5):752-60. doi: 10.1016/j.jaad.2011.04.022. Epub 2011 Sep 9. — View Citation

Chen FY, Zhou J, Guo N, Ma WG, Huang X, Wang H, Yuan ZY. Curcumin retunes cholesterol transport homeostasis and inflammation response in M1 macrophage to prevent atherosclerosis. Biochem Biophys Res Commun. 2015 Nov 27;467(4):872-8. doi: 10.1016/j.bbrc.2015.10.051. Epub 2015 Oct 19. — View Citation

Dallal, G (2017). Randomization.com. Retrieved from http://www.randomization.com

Doyle R, Sadlier DM, Godson C. Pro-resolving lipid mediators: Agents of anti-ageing? Semin Immunol. 2018 Dec;40:36-48. doi: 10.1016/j.smim.2018.09.002. Epub 2018 Oct 4. — View Citation

Fiala M, Terrando N, Dalli J. Specialized Pro-Resolving Mediators from Omega-3 Fatty Acids Improve Amyloid-beta Phagocytosis and Regulate Inflammation in Patients with Minor Cognitive Impairment. J Alzheimers Dis. 2016;49(4):1191. doi: 10.3233/JAD-159008. No abstract available. — View Citation

Hewlings SJ, Kalman DS. Curcumin: A Review of Its Effects on Human Health. Foods. 2017 Oct 22;6(10):92. doi: 10.3390/foods6100092. — View Citation

Krishnakumar, I, Abhilash, M., Gopakumar, G.,et al. Improved blood-brain-barrier permeability and tissue distribution following the oral administration of a food-grade formulation of curcumin with fenugreek fibre. J. Funct Foods, 14, 215-225

Kumar, D., Jacob, D., Subash. P. et al. (2016). Enhanced bioavailability and relative distribution of free (unconjugated) curcuminoids following the oral administration of a food-grade formulation with fenugreek dietary fibre: A randomised double-blind crossover study. J Funt Foods, 22, 578-587

Lopez-Vicario C, Rius B, Alcaraz-Quiles J, Garcia-Alonso V, Lopategi A, Titos E, Claria J. Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases. Eur J Pharmacol. 2016 Aug 15;785:133-143. doi: 10.1016/j.ejphar.2015.03.092. Epub 2015 May 15. — View Citation

Madhu K, Chanda K, Saji MJ. Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial. Inflammopharmacology. 2013 Apr;21(2):129-36. doi: 10.1007/s10787-012-0163-3. Epub 2012 Dec 16. — View Citation

Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant. 2006 Jul;25(7):834-8. doi: 10.1016/j.healun.2006.03.005. Epub 2006 May 24. — View Citation

Menon VP, Sudheer AR. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol. 2007;595:105-25. doi: 10.1007/978-0-387-46401-5_3. — View Citation

Nathan C, Ding A. Nonresolving inflammation. Cell. 2010 Mar 19;140(6):871-82. doi: 10.1016/j.cell.2010.02.029. — View Citation

Nordgren TM, Anderson Berry A, Van Ormer M, Zoucha S, Elliott E, Johnson R, McGinn E, Cave C, Rilett K, Weishaar K, Maddipati SS, Appeah H, Hanson C. Omega-3 Fatty Acid Supplementation, Pro-Resolving Mediators, and Clinical Outcomes in Maternal-Infant Pairs. Nutrients. 2019 Jan 5;11(1):98. doi: 10.3390/nu11010098. — View Citation

Norling LV, Ly L, Dalli J. Resolving inflammation by using nutrition therapy: roles for specialized proresolving mediators. Curr Opin Clin Nutr Metab Care. 2017 Mar;20(2):145-152. doi: 10.1097/MCO.0000000000000353. — View Citation

Norris PC, Skulas-Ray AC, Riley I, Richter CK, Kris-Etherton PM, Jensen GL, Serhan CN, Maddipati KR. Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation. Sci Rep. 2018 Dec 21;8(1):18050. doi: 10.1038/s41598-018-36679-4. Erratum In: Sci Rep. 2019 Dec 19;9(1):19816. — View Citation

Panahi Y, Hosseini MS, Khalili N, Naimi E, Simental-Mendia LE, Majeed M, Sahebkar A. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. Biomed Pharmacother. 2016 Aug;82:578-82. doi: 10.1016/j.biopha.2016.05.037. Epub 2016 Jun 6. — View Citation

Pandaran Sudheeran S, Jacob D, Natinga Mulakal J, Gopinathan Nair G, Maliakel A, Maliakel B, Kuttan R, Im K. Safety, Tolerance, and Enhanced Efficacy of a Bioavailable Formulation of Curcumin With Fenugreek Dietary Fiber on Occupational Stress: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. J Clin Psychopharmacol. 2016 Jun;36(3):236-43. doi: 10.1097/JCP.0000000000000508. — View Citation

Saji S, Asha S, Svenia PJ, Ratheesh M, Sheethal S, Sandya S, Krishnakumar IM. Curcumin-galactomannoside complex inhibits pathogenesis in Ox-LDL-challenged human peripheral blood mononuclear cells. Inflammopharmacology. 2018 Oct;26(5):1273-1282. doi: 10.1007/s10787-018-0474-0. Epub 2018 Apr 9. — View Citation

Serhan CN. Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Aspects Med. 2017 Dec;58:1-11. doi: 10.1016/j.mam.2017.03.001. Epub 2017 Mar 3. — View Citation

So J, Wu D, Lichtenstein AH, Tai AK, Matthan NR, Maddipati KR, Lamon-Fava S. EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: A randomized, double-blind, crossover study. Atherosclerosis. 2021 Jan;316:90-98. doi: 10.1016/j.atherosclerosis.2020.11.018. Epub 2020 Dec 7. — View Citation

Spite M, Claria J, Serhan CN. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab. 2014 Jan 7;19(1):21-36. doi: 10.1016/j.cmet.2013.10.006. Epub 2013 Nov 14. — View Citation

T Krishnareddy N, Thomas JV, Nair SS, N Mulakal J, Maliakel BP, Krishnakumar IM. A Novel Curcumin-Galactomannoside Complex Delivery System Improves Hepatic Function Markers in Chronic Alcoholics: A Double-Blinded, randomized, Placebo-Controlled Study. Biomed Res Int. 2018 Sep 23;2018:9159281. doi: 10.1155/2018/9159281. eCollection 2018. Erratum In: Biomed Res Int. 2019 Mar 3;2019:5673740. — View Citation

Wongcharoen W, Jai-Aue S, Phrommintikul A, Nawarawong W, Woragidpoonpol S, Tepsuwan T, Sukonthasarn A, Apaijai N, Chattipakorn N. Effects of curcuminoids on frequency of acute myocardial infarction after coronary artery bypass grafting. Am J Cardiol. 2012 Jul 1;110(1):40-4. doi: 10.1016/j.amjcard.2012.02.043. Epub 2012 Apr 3. — View Citation

Yu Y, Shen Q, Lai Y, Park SY, Ou X, Lin D, Jin M, Zhang W. Anti-inflammatory Effects of Curcumin in Microglial Cells. Front Pharmacol. 2018 Apr 20;9:386. doi: 10.3389/fphar.2018.00386. eCollection 2018. — View Citation

* Note: There are 30 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of the mean or median change in high sensitivity C-reactive protein (hs-CRP) relative to baseline	Mean or median change in high sensitivity C-reactive protein (hs-CRP) from baseline to Day 60	60 days
Secondary	Assessment of the mean or median change in Interleukin-6 (IL-6) relative to baseline	Mean or median change in IL-6 from baseline to Day 60	60 days
Secondary	Assessment of the mean or median change in Tumor Necrosis Factor-alpha (TNF-alpha) relative to baseline	Mean or median change in TNF-alpha from baseline to Day 60	60 days
Secondary	Assessment of the mean or median change in Erythrocyte Sedimentation Rate (ESR) relative to baseline	Mean or median change in ESR from baseline to Day 60	60 days
Secondary	Assessment of the mean or median change in Fibrinogen Activity relative to baseline	Mean or median change in Fibrinogen Activity from baseline to Day 60	60 days